Abstracts tagged "COVID-19"

Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants
Greta Mastrangelo¹, Ellen Go², Paul Tsoukas², Hua Lu³, Amy Xu², Arthur Hoi Hin Cheng² and Rae Yeung⁴, ¹The Hospital of Sick Children,Department of Paediatrics, University of Toronto, Division of Rheumatology, Toronto, ON, Canada, ²The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…
Abstract Number: 035 • 2023 Pediatric Rheumatology Symposium
SARS-CoV-2 Vaccination of Children with a History of Multisystem Inflammatory Syndrome
Mariana Sanchez Villa¹, Matthew Wisniewski¹, Jessica Nguyen¹, Eyal Muscal¹, Marietta Deguzman², Sara Kristen Sexson Tejtel¹, Sridevi Devaraj¹, Flor Munoz-Rivas¹, Leila Sahni¹ and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Most children who contract SARS-CoV-2 are asymptomatic or mildly symptomatic, but a subset subsequently develop the hyperinflammatory condition called multisystem inflammatory syndrome in children…
Abstract Number: 055 • 2023 Pediatric Rheumatology Symposium
COVID-19 Vaccination in Children with Rheumatic Diseases: Results of a CARRA-wide Survey
Beth Rutstein¹, Merav Heshin Bekenstein², Maria Schletzbaum³, Nora Singer⁴, Rebecca Sadun⁵, Melanie Kohlheim⁶, Vincent Del Gaizo⁷, Kelly Wise⁸, Melica Nikahd⁹, Guy Brock⁹, Monica Ardura⁸, Vidya Sivaraman¹⁰ and For the CARRA Investigators¹¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Medical College of Wisconsin, Milwaukee, WI, ⁴Metro Health, Cleveland, OH, ⁵Duke University, Durham, NC, ⁶None, Columbus, OH, ⁷CARRA, Washington, DC, ⁸Nationwide Children's Hospital, Columbus, OH, ⁹The Ohio State University, Columbus, OH, ¹⁰Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ¹¹Duke University Medical Center, Durham, NC
Background/Purpose: Children receiving immunosuppressive therapies (IST) have a higher risk of hospitalization from COVID-19. COVID-19 vaccines significantly reduce the likelihood of severe disease or death.…
Abstract Number: 070 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Patients with Juvenile Idiopathic Inflammatory Myopathies
Dawn Wahezi¹, Dominique Jerome¹, Evin Rothschild¹, Jeffrey Dvergsten², Stacey Tarvin³, Susan Kim⁴ and Tamar Rubinstein¹, ¹Children's Hospital at Montefiore, New York, NY, ²Duke University Hospital, Durham, NC, ³Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ⁴UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Since the onset of the COVID-19 pandemic, there have been concerns regarding the risks of SARS-CoV-2 infection in patients with juvenile idiopathic inflammatory myopathies…
Abstract Number: 076 • 2023 Pediatric Rheumatology Symposium
COVID-Distress in Children with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Brooke Rezmer¹, Michelle Adler², Tamar Rubinstein³, Andrea Knight⁴ and Natoshia Cunningham⁵, ¹Michigan State University College of Human Medicine, Grand Rapids, MI, ²Michigan State University, East Lansing, ³Children's Hospital at Montefiore, New York, NY, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Michigan State University, Grand Rapids, MI
Background/Purpose: Psychological symptoms are common in childhood-onset systemic lupus erythematosus (cSLE) and may impact other psychological and health-related outcomes. Mental health problems such as anxiety…
Abstract Number: 087 • 2023 Pediatric Rheumatology Symposium
Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic
Rebecca Hetrick¹, Maria Pereira² and Marietta De Guzman³, ¹Indiana University School of Medicine, Indianapolis, IN, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The COVID-19 pandemic created dramatic societal disruptions. Social distancing and measures to reduce disease spread rapidly reshaped healthcare delivery. Recognizing the burden of frequent…
Abstract Number: 097 • 2023 Pediatric Rheumatology Symposium
Survey of Covid-19 Immunization and Infection in Patients with Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease
Mariana Correia Marques¹, Paul Subrata², Carol Lake³, Ly-Lan Bergeron⁴, Rashmi Sinha⁵, Luciana Peixoto⁶, Marinka Twilt⁷ and Michael Ombrello⁸, ¹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases/Children`s National Hospital, Bethesda, MD, ²NIAID Collaborative Bioinformatics Resource (NCBR), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³NIH, GAITHERSBURG, MD, ⁴NIH/NIAMS, Vienna, VA, ⁵Systemic JIA Foundation, Cincinnati, OH, ⁶Systemic JIA Foundation, Cincinnati, ⁷Alberta Children's Hospital, Calgary, AB, Canada, ⁸Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, North Bethesda, MD
Background/Purpose: Immunization is one of the most important tools for the control of the Covid-19 pandemic. The safety and effectiveness of the Covid-19 immunizations have…
Abstract Number: L08 • ACR Convergence 2022
Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Christopher Podgorski¹ and Deborah Parks², ¹BJC/Washington University Consortium, St. Louis, MO, ²Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Treatment with Tixagevimab/Cilgavimab 150/150 mg was authorized by the FDA on 12/8/21 under an Emergency Use Authorization as pre-exposure prophylaxis against COVID-19 infection. The…
Abstract Number: 0177 • ACR Convergence 2022
COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey
Mrinalini Dey¹, Naveen R², Elena Nikiphorou³, Parikshit Sen⁴, James B. Lilleker⁵, Vishwesh Agarwal⁶, Sinan Kardes⁷, Jessica Day⁸, Marcin Milchert⁹, Mrudula Joshi¹⁰, Tamer A Gheita¹¹, Babur Salim¹², Tsvetelina Velikova¹³, Abraham Edgar Gracia-Ramos¹⁴, Ioannis Parodis¹⁵, Albert Selva O’Callaghan¹⁶, Minchul Kim¹⁷, Tulika Chatterjee¹⁷, Ai Lyn Tan¹⁸, Ashima Makol¹⁹, Arvind Nune²⁰, Lorenzo Cavagna²¹, Miguel Angel Saavedra Salinas²², Samuel Shinjo²³, Nelly Ziade²⁴, Johannes Knitza²⁵, Masataka Kuwana²⁶, Oliver Distler²⁷, Hector Chinoy²⁸, John Pauling²⁹, Chris Wincup³⁰, Vikas Agarwal², Rohit Aggarwal³¹ and Latika Gupta³², ¹Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Leiden University Medical Center & King's College London, London, United Kingdom, ⁴Maulana Azad Medical College, New Delhi, India, ⁵The University of Manchester, Manchester, United Kingdom, ⁶Mahatma Gandhi Missions Medical College, Lucknow, India, ⁷Istanbul University, Istanbul, Turkey, ⁸Walter and Eliza Hall Institute, Melbourne, Australia, ⁹Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁰Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ¹¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹²Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ¹³Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁴Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ¹⁵Karolinska Institutet, Stockholm, Sweden, ¹⁶Hospital Universitari Vall d'Hebron, Barcelona, Spain, ¹⁷University of Illinois College of Medicine Peoria, Peoria, IL, ¹⁸University of Leeds, Leeds, United Kingdom, ¹⁹Mayo Clinic, Rochester, MN, Rochester, MN, ²⁰Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ²¹Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ²²IMSS, Ciudad de México, Mexico, ²³Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ²⁴Saint-Joseph University, Beirut, Lebanon, ²⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²⁶Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²⁸The University of Manchester, Sale, United Kingdom, ²⁹North Bristol NHS Trust, Bristol, United Kingdom, ³⁰Rayne Institute, University College London, London, United Kingdom, ³¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³²Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: COVID-19 vaccines are safe and effective, though patients with rare rheumatic diseases like idiopathic inflammatory myositis (IIMs), and those with multiple comorbidities continue to…
Abstract Number: 0566 • ACR Convergence 2022
SARS-CoV-2-Specific T Cell Responses in Multisystem Inflammatory Syndrome in Children
Ki Pui Lam¹, Marcos H. Chinas², Amélie M. Julé², Maria Taylor³, Mary Beth F. Son¹, Janet Chou², Jane W. Newburger⁴, Adrienne G. Randolph⁵, Maria Gutierrez-Arcelus² and lauren henderson¹, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Brighton, MA, ⁴Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Critical Care Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) develops about a month after SARS-CoV-2 infection and this delayed presentation suggests a role for the adaptive immune…
Abstract Number: 0759 • ACR Convergence 2022
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study
Gordon Lam¹, Andrew Laster¹, Heather Gladue¹, Ahmad Kashif¹, Erin Siceloff², Victoria Lackey¹, Cheryl Robertson¹, Ashley Toci¹, Maggie McCarter³ and Leonard Calabrese⁴, ¹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Arthritis and Osteoporosis Consultants of the Carolinas, Stallings, NC, ³University of South Carolina, Columbia, SC, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is uncertain as these individuals were not included in clinical…
Abstract Number: 0789 • ACR Convergence 2022
The Persistence of Anti-Spike Antibodies Following Two SARS-CoV-2 Vaccine Doses in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy Compared to Healthy Controls: A Prospective Cohort Study
Ingrid Egeland Christensen¹, Ingrid Jyssum¹, Anne Therese Tveter¹, Joe Sexton¹, Siri Mjaaland², Grete Birkeland Kro³, Tore K. Kvien¹, David Warren³, Jørgen Jahnsen⁴, Ludvig A. Munthe³, Espen Haavardsholm¹, Gunnveig Grødeland³, Kristin Kaasen Jørgensen⁴, Silje Watterdal Syversen¹, Guro Løvik Goll¹ and Sella Aarrestad Provan¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Norwegian Institute of Public Health, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Akershus University Hospital, Oslo, Norway
Background/Purpose: The durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not well characterized. The aim…
Abstract Number: 0882 • ACR Convergence 2022
Gender Differences in Rheumatology Authorship: A Bibliometric Analysis of High Impact Rheumatology Journals from 2019-2021
Neha Chaurasia¹, Priyanka Iyer¹ and Melody Esmaeili-Ghahfarokhi², ¹University of California Irvine, Orange, CA, ²University of California Irvine, Orange
Background/Purpose: Recent data suggests the COVID-19 pandemic disproportionately affected productivity of women in the workforce. This bibliometric analysis examines gender differences in authorship of manuscripts…
Abstract Number: 1213 • ACR Convergence 2022
Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021
Joyce (Yun-Ting) Huang¹, David Jenkins², Belay Birlie Yimer¹, Jose Benitez-Aurioles², Niels Peek², Mark Lunt¹, Will Dixon³ and Meghna Jani¹, ¹Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, ²Division of Informatics, The University of Manchester, Manchester, United Kingdom, ³The University of Manchester, Manchester, United Kingdom
Background/Purpose: Opioid prescribing has contributed to a North American epidemic with increasing trends in several European countries. Rheumatic and musculoskeletal diseases (RMDs) are one of…
Abstract Number: 1756 • ACR Convergence 2022
Adverse Events in Patients with Inflammatory Joint Diseases: Results from the EULAR Coronavirus Vaccine (COVAX) Physician-reported Registry
Ana Lúcia Martins Fernandes¹, Jose A Gomez-Puerta², Juan Camilo Sarmiento-Monroy², Saskia Lawson-Tovey³, Kimme Hyrich⁴, Laure Gossec⁵, Loreto Carmona⁶, Anja Strangfeld⁷, Elsa Mateus⁸, Ana Maria Rodrigues⁹, Eric Hachulla¹⁰, Marta Mosca¹¹, Patrick Durez¹², Bernd Raffeiner¹³, Nicolas Roux¹⁴, Viellard Eric¹⁵, Olivier Brocq¹⁶, Julija Zepa¹⁷, Inita Bulina¹⁸, Eva Strakova¹⁹, Vanda Mlynarikova²⁰, Emoke Šteňová²¹, Martin Soubrier²², Xavier Mariette²³ and Pedro Machado²⁴, ¹Centro Hospitalar Universitário do Algarve, Faro, Portugal, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴The University of Manchester, Manchester, United Kingdom, ⁵Sorbonne Université, Paris, France, ⁶Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁷Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁸EULAR, Lisboa, Portugal, ⁹Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, ¹⁰University of Lille, LILLE, France, ¹¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹²Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ¹³Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy, ¹⁴Service de Rhumatologie, Hôpital Robert Schuman, Metz, France, ¹⁵Private practice, St. Malo, France, ¹⁶Rheumatology- CH Princesse Grace, Monaco, Monaco, ¹⁷Riga Stradins University, Latvia, Pauls Stradins Clinical University Hospital, Centre of Rheumatology, Riga, Latvia, Riga, Latvia, ¹⁸Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, Riga, Latvia, ¹⁹Department of Internal Medicine, Faculty Hospital Prešov, Presov, Slovakia, ²⁰National Institute of Rheumatic Diseases, Piešťany, Slovakia, ²¹University Hospital, Bratislava, Slovakia, ²²Gabriel-Montpied Hospital, Clermont-Ferrand, France, ²³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²⁴University College London, London, United Kingdom
Background/Purpose: Patients with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMDs) were excluded from SARS-CoV-2 vaccination development programs. Therefore, concerns regarding the safety and effectiveness of SARS-CoV-2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].